See the Glossary for more terms.
Concepts represent early planning stages for program announcements, request for applications, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to the Opportunities and Announcements portal.
NB: Council approval does not guarantee that a concept will become an initiative.
Request for Applications (R01)
Contact: Michael Schaefer
Objective: Preclinical development of select candidate diagnostics with an emphasis on antimicrobial resistance.
Description: This initiative will support milestone-driven projects focused on advancing candidate diagnostics and/or diagnostic platforms through the product development pathway. Responsive projects will include preliminary data establishing proof of principle for target candidate diagnostics. Participation with industrial laboratories will be required to facilitate appropriate and validated product development activities.
Emphasis will be on developing rapid, sensitive, specific, easy to use, and adaptable medical diagnostics for use in a primary healthcare setting including a physician's office, health clinic, emergency departments, at the bedside, and/or low resource settings to detect NIAID Category A-C agents, emerging and reemerging pathogens, or pathogens in disease areas where antimicrobial drug resistance is of clinical concern. Multiplex diagnostic platforms are of high priority that focus on integrated sample-to-answer technologies capable of rapidly and sensitively detecting multiple agents and their drug sensitivities, including invasive pathogens from normally sterile sources; rapidly distinguishing whether an individual is infected with a threat agent or a common infection with similar, generalized symptoms; and detecting early, nonspecific symptoms in human clinical samples using previously identified pathogen- or host-specific targets. Clinical trials will not be supported under this program.
Request for Applications (R21/R33)
Objective: To stimulate innovation in the discovery and development of novel therapies for infections caused by resistant gram-negative bacteria and multiple subtypes of influenza A, including drug resistant influenza.
Description: This initiative seeks to stimulate innovation in the discovery and development of novel therapies for infections caused by selected resistant pathogens of significant clinical concern. Examples of areas to be supported related to bacterial pathogens include novel approaches to exploit bacterial transport mechanisms to facilitate the uptake of anti-gram-negative small molecules; developing efflux pump blockers; discovering novel compounds to protect antibacterials from bacterial enzymatic modification and destruction; novel approaches to combat porin downregulation; developing biofilm inhibitors to render bacteria more susceptible to antibacterials; and developing inhibitors of the bacterial stress response system to prevent upregulation of resistance genes in response to antibacterial agents. In addition, agents directed towards unexploited gram-negative targets as well as novel members of existing classes of approved antibacterials with substantially improved resistance profiles are eligible. Projects must focus on novel treatment strategies for gram-negative pathogens where antimicrobial resistance threatens effective treatment, including Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, pathogenic Escherichia coli, and Neisseria gonorrhoeae.
Examples of areas to be supported related to influenza include discovering and developing novel viral or host-targeted small molecule-based interventions, including compounds that modulate the immune response or target host factors involved in the viral life cycle; optimizing antiviral candidates with oral bioavailability and a novel mechanism of action (different from neuraminidase inhibition); and identifying and validating new drug targets on the virus or host.
Objective: To encourage the translation of basic research findings for developing effective treatments for human infections caused by anaerobic protozoa such as Giardia lamblia, Entamoeba histolytica and related free-living species of amoeba, and Trichomonas vaginalis.
Description: This initiative encourages developing novel interventions for treating infectious diseases of humans caused by anaerobic protozoa (e.g., amebiasis, giardiasis, and trichomoniasis). Projects eligible for funding under this initiative would include developing small molecule inhibitors and adjunctive therapeutics targeting resistance mechanisms.
Early stage translational and/or preclinical projects might include:
For the published program announcement identifying location of peer review, see the January 30, 2014, Guide announcement, International Research in Infectious Diseases, Including AIDS (R01).
For the published requests for applications, see the November 27, 2013, Guide announcements, International Collaborations in Infectious Diseases Research (U01) and International Collaborations in Infectious Diseases Research (U19).
Last Updated January 30, 2014
Last Reviewed January 30, 2014